skip to the content

Clinical Trials

Parkinson’s Disease - Efficacy and Safety of Sufinamide (B10-026)

Protocol ID

B10-026

Protocol Description

Safinamide is a substance being developed as add-on therapy for the treatment of Parkinson’s disease and acts by increasing the available dopamine in those areas of the brain where dopamine is decreased as a result of your illness. Dopamine in the brain is involved in controlling body movements. Safinamide has been extensively studied in animals, and has shown to increase the level of dopamine in these animals. Safinamide has also been tested in patients with Parkinson’s disease. The goal of this research trial is to see if safinamide is safe and well tolerated, and can potentially improve the symptoms of Parkinson’s disease. Data from this trial may provide essential information about the effectiveness and safety of safinamide in patients with Parkinson’s disease, who are already receiving a stable dose of their normal Parkinson’s disease treatment.

 

Eligibility Criteria

•    Men and women between the ages 30 - 80
•    Persons diagnosed with idiopathic Parkinson’s disease for more than 3 years

Primary Investigator(s)

  • Michael Pourfar, MD

Contact Information

Jean Ayan
(516) 562-2426
jayan@nshs.edu

Last Update

December 21, 2010
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Neurosciences:
top
top